Not logged inImmunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study
Christofides, Elena A.; Puente, Orlando; Norwood, Paul; Denham, Douglas; Maheshwari, Hiralal; Lillestol, Michael; Hart, Terence; Nakhle, Samer; Chadha, Anurekha; Fitz-Patrick, David; Sugimoto, Danny; Soufer, Joseph; Young, Douglas; Warren, Mark; Huffman, David; Reed, John; Bays, Harold; Arora, Samir; Rizzardi, Barbara; Tidman, Raymond; Rendell, Marc; Johnson, Kimball A. .png)
Share.png)
SaveSafety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trialMurray, Joseph A.; Wassaf, Dina; Dunn, Karen; Arora, Samir; Winkle, Peter; Stacey, Helen; Cooper, Simon; Goldstein, Kaela E.; Manchanda, Rajesh; Kontos, Stephan; Grebe, Kristie M. Share Save Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine A Phase 3 Randomized Clinical TrialVesikari, Timo; Finn, Adam; van Damme, Pierre; Leroux-Roels, Isabel; Leroux-Roels, Geert; Segall, Nathan; Toma, Azhar; Vallieres, Gerald; Aronson, Ronnie; Reich, Dennis; Arora, Samir; Ruane, Peter J.; Cone, Clancy L.; Manns, Michael; Cosgrove, Catherine; Faust, Saul N.; Ramasamy, Maheshi N.; Machluf, Nathalie; Spaans, Johanna N.; Yassin-Rajkumar, Bebi; Anderson, David; Popovic, Vlad; Diaz-Mitoma, Francisco Share Save Share Save Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPDMartinez, Fernando J.; Rabe, Klaus F.; Ferguson, Gary T.; Fabbri, Leonardo M.; Rennard, Stephen; Feldman, Gregory J.; Sethi, Sanjay; Spangenthal, Selwyn; Gottschlich, Gregory M.; Rodriguez-Roisin, Roberto; Arora, Samir; Siler, Thomas M.; Siddiqui, Shahid; Darken, Patrick; Fischer, Tracy; Maes, Andrea; Golden, Michael; Orevillo, Chad; Reisner, Colin Share Save Share Save Pooled analysis of 24-h lung function following treatment with the LAMA/LABA glycopyrronium/formoterol fumarate fixed-dose combination, delivered by a novel MDI co-suspension technology (GFF MDI), in COPD patients (pts)Reisner, Colin; Gottschlich, Gregory; Fakih, Faisal; Koser, Andras; Krainson, James; Delacruz, Luis; Arora, Samir; Feldman, Gregory; Pudi, Krishna; Siddiqui, Shahid; Orevillo, Chad; Maes, Andrea Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
